▶ CJC-1295 · SUBTOPIC · DOSING LITERATURE
CJC-1295 Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of CJC-1295. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for CJC-1295 reports the following route(s) of administration: Subcutaneous (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of CJC-1295.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for CJC-1295 of approximately ~30 minutes (No DAC) · ~1 week (with DAC). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of CJC-1295. Refer to the original publication for full protocol detail.
- Teichman SL, Neale A, Lawrence B, et al. (2006) reports the CJC-1295 protocol used in Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults, published in J Clin Endocrinol Metab. PMID 16352683. See the source for the protocol-level dose range, frequency, and duration. link
- Sinha DK, Balasubramanian A, Tatem AJ, et al. (2020) reports the CJC-1295 protocol used in Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males, published in Transl Androl Urol. PMID 32257854. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What is CJC-1295?
CJC-1295 is a synthetic 30-amino-acid analog of growth-hormone-releasing hormone GHRH(1-29) developed by ConjuChem in the 2000s as a long-acting research compound. Two pharmacokinetic variants exist: with DAC (covalent albumin-binding linker, ~1-week half-life) and No DAC (Mod GRF 1-29, ~30-minute half-life).
▶ CJC-1295 vs sermorelin · what's the difference?
Sermorelin is the unmodified native GHRH(1-29) with rapid DPP-IV cleavage. CJC-1295 retains four stabilizing amino-acid substitutions (Ala2→D-Ala, Arg15→Gln, Leu27→Ala, Asp28→Ser) that resist DPP-IV. The No-DAC variant has the same half-life as sermorelin (~30 min) but resists cleavage. The with-DAC variant adds a maleimidopropionic-acid linker for ~1-week half-life.
▶ What is the difference between CJC-1295 with DAC and No DAC?
The DAC (Drug Affinity Complex) variant carries a maleimidopropionic-acid linker that covalently binds plasma albumin in vivo, extending half-life to roughly one week. The No-DAC variant lacks the linker and has the same ~30-min half-life as native GHRH. Most current research uses No DAC; the with-DAC ConjuChem clinical program was halted.
▶ How is CJC-1295 dosed in research?
Community-reported research protocols use CJC-1295 No DAC at 100-300 mcg per administration, paired 1:1 by mass with ipamorelin, 1-3 times daily, subcutaneous. With-DAC historical protocols used 1-2 mg per week. No human dose is recommended by this wiki.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · 4 °C 24 months
Reconstituted · 2-8 °C, 28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Not FDA-approved. ConjuChem clinical program for the with-DAC variant halted in mid-2000s after two deaths in a lipodystrophy trial. Causality not definitively established.
WADA · Prohibited at all times under WADA Section S2 (GHRH-analog sub-category).
RELATED PAGES
▶ LAST UPDATED · 2026-05-25